CN109170470A - 一种治疗糖尿病的固体饮料及其制备方法 - Google Patents
一种治疗糖尿病的固体饮料及其制备方法 Download PDFInfo
- Publication number
- CN109170470A CN109170470A CN201811179109.0A CN201811179109A CN109170470A CN 109170470 A CN109170470 A CN 109170470A CN 201811179109 A CN201811179109 A CN 201811179109A CN 109170470 A CN109170470 A CN 109170470A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- extract
- solid beverage
- acid
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 28
- 239000007787 solid Substances 0.000 title claims abstract description 21
- 235000013361 beverage Nutrition 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 49
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 23
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 20
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 20
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 20
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011782 vitamin Substances 0.000 claims abstract description 15
- 241000894006 Bacteria Species 0.000 claims abstract description 14
- 241000124033 Salix Species 0.000 claims abstract description 14
- 240000008042 Zea mays Species 0.000 claims abstract description 13
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 12
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- 235000021329 brown rice Nutrition 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- 235000001537 Ribes X gardonianum Nutrition 0.000 claims abstract description 11
- 235000001535 Ribes X utile Nutrition 0.000 claims abstract description 11
- 235000016919 Ribes petraeum Nutrition 0.000 claims abstract description 11
- 244000281247 Ribes rubrum Species 0.000 claims abstract description 11
- 235000002355 Ribes spicatum Nutrition 0.000 claims abstract description 11
- 235000007244 Zea mays Nutrition 0.000 claims abstract description 11
- 229940089639 cornsilk Drugs 0.000 claims abstract description 11
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 11
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 11
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 11
- 239000001231 zea mays silk Substances 0.000 claims abstract description 11
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000219099 Parthenocissus quinquefolia Species 0.000 claims abstract description 10
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims abstract description 10
- 244000248825 Peltandra virginica Species 0.000 claims abstract description 10
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 10
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 10
- 229960000304 folic acid Drugs 0.000 claims abstract description 10
- 235000019152 folic acid Nutrition 0.000 claims abstract description 10
- 239000011724 folic acid Substances 0.000 claims abstract description 10
- 230000035784 germination Effects 0.000 claims abstract description 10
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 10
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 10
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 10
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 10
- 229960003080 taurine Drugs 0.000 claims abstract description 10
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 10
- 239000011719 vitamin A Substances 0.000 claims abstract description 10
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 10
- 239000011718 vitamin C Substances 0.000 claims abstract description 10
- 229940045997 vitamin a Drugs 0.000 claims abstract description 10
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 10
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 10
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 9
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 claims abstract description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 9
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 9
- 238000000855 fermentation Methods 0.000 claims abstract description 9
- 230000004151 fermentation Effects 0.000 claims abstract description 9
- 239000000787 lecithin Substances 0.000 claims abstract description 9
- 235000010445 lecithin Nutrition 0.000 claims abstract description 9
- 229940067606 lecithin Drugs 0.000 claims abstract description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960002477 riboflavin Drugs 0.000 claims abstract description 9
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 9
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 9
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 9
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 9
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 8
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 8
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 7
- 230000000996 additive effect Effects 0.000 claims abstract description 7
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 6
- YZHOZVWZUXBPMD-UHFFFAOYSA-N calcium;3-hydroxy-3-methylbutanoic acid Chemical compound [Ca].CC(C)(O)CC(O)=O YZHOZVWZUXBPMD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960003495 thiamine Drugs 0.000 claims abstract description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 6
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 6
- 240000007594 Oryza sativa Species 0.000 claims description 9
- 235000007164 Oryza sativa Nutrition 0.000 claims description 8
- -1 hydroxyl isomaltulose Chemical compound 0.000 claims description 8
- 235000009566 rice Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- FYPVXEILSNEKOO-UHFFFAOYSA-L calcium;butanoate Chemical compound [Ca+2].CCCC([O-])=O.CCCC([O-])=O FYPVXEILSNEKOO-UHFFFAOYSA-L 0.000 claims 1
- 239000010977 jade Substances 0.000 claims 1
- 210000004681 ovum Anatomy 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 42
- 102000004877 Insulin Human genes 0.000 abstract description 21
- 108090001061 Insulin Proteins 0.000 abstract description 21
- 229940125396 insulin Drugs 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 19
- 238000002347 injection Methods 0.000 abstract description 11
- 239000007924 injection Substances 0.000 abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 10
- 239000008103 glucose Substances 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 6
- 230000000630 rising effect Effects 0.000 abstract description 3
- 241000219051 Fagopyrum Species 0.000 description 14
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- KERAKVNUJVKGKO-UHFFFAOYSA-N calcium;2-methylbutanoic acid Chemical compound [Ca].CCC(C)C(O)=O KERAKVNUJVKGKO-UHFFFAOYSA-N 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XLSLFPQAPYONPW-WHUHBCJBSA-N (2s,3s,4s,5r,6r)-6-[(r)-cyano(phenyl)methoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H](C#N)C1=CC=CC=C1 XLSLFPQAPYONPW-WHUHBCJBSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- WKBPZYKAUNRMKP-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)pentyl]1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CCC)CN1C=NC=N1 WKBPZYKAUNRMKP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 229920000018 Callose Polymers 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YZNNBIPIQWYLDM-HSUXUTPPSA-N Fagomine Chemical compound OC[C@H]1NCC[C@@H](O)[C@@H]1O YZNNBIPIQWYLDM-HSUXUTPPSA-N 0.000 description 1
- YZNNBIPIQWYLDM-ZLUOBGJFSA-N Fagomine Natural products OC[C@@H]1NCC[C@H](O)[C@H]1O YZNNBIPIQWYLDM-ZLUOBGJFSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- YZNNBIPIQWYLDM-UHFFFAOYSA-N L-fagomine Natural products OCC1NCCC(O)C1O YZNNBIPIQWYLDM-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UNGXBWFICNLIRX-UHFFFAOYSA-N Laetrile Natural products NCC(OC1OC(C(O)C(O)C1O)C(=O)O)c2ccccc2 UNGXBWFICNLIRX-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- BGMYHTUCJVZIRP-UHFFFAOYSA-N Nojirimycin Natural products OCC1NC(O)C(O)C(O)C1O BGMYHTUCJVZIRP-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000123125 Phylloporia ribis Species 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- SGJNQVTUYXCBKH-HNQUOIGGSA-N hispidin Chemical compound O1C(=O)C=C(O)C=C1\C=C\C1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-HNQUOIGGSA-N 0.000 description 1
- SGJNQVTUYXCBKH-UHFFFAOYSA-N hispidin Natural products O1C(=O)C=C(O)C=C1C=CC1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- BGMYHTUCJVZIRP-GASJEMHNSA-N nojirimycin Chemical compound OC[C@H]1NC(O)[C@H](O)[C@@H](O)[C@@H]1O BGMYHTUCJVZIRP-GASJEMHNSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011031 topaz Substances 0.000 description 1
- 229910052853 topaz Inorganic materials 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗糖尿病的固体饮料及其制备方法，其中，固体饮料包含发芽糙米粉、小分子肽、青钱柳提取物、茶藨子叶状层菌发酵菌丝体、玉米须提取物、桑叶提取物、苦荞提取物、卵磷脂、茯苓提取物、显齿蛇葡萄叶粉、β‑羟基‑β甲基丁酸钙、左旋肉碱、氧化镁、维生素C、牛磺酸、葡萄糖酸锌、烟酸、维生素E、泛酸、维生素B1、维生素B2、维生素B6、维生素B12、维生素A、叶酸、维生素D3、添加剂。本发明具有能够抑制血糖上升的效果，并且可以让糖尿病患者摆脱注射胰岛素的困扰,可逐渐代替胰岛素，让患者摆脱对胰岛素及西药的依赖，从而避免胰岛素的副作用。
Description
技术领域
本发明涉及一种治疗糖尿病的固体饮料及其制备方法。
背景技术
糖尿病是一组以高血糖为特征的代谢性疾病。高血糖则是由于胰岛素分泌缺陷或其生物作用受损，或两者兼有引起。糖尿病时长期存在的高血糖，导致各种组织，特别是眼、肾、心脏、血管、神经的慢性损害、功能障碍。目前尚无根治糖尿病的方法，治疗药物多为：磺脲类药物、双胍类降糖药、α葡萄糖苷酶抑制剂、胰岛素增敏剂、格列奈类胰岛素促分泌剂等口服药物，或者采用主色胰岛素制剂的方式。
现阶段治疗糖尿病，大多是靠降糖药，对身体肝脏等器官有很大的副作用，糖尿病的药物选择成为了患者们最为头疼的事情，严重的患者靠胰岛素来降糖。
发明内容
本发明的目的在于提供一种治疗糖尿病的固体饮料及其制备方法。
本发明解决上述问题所采用的技术方案是：
一种治疗糖尿病的固体饮料，其特征在于：按重量百分比计，由以下成分构成，发芽糙米粉26％～39％、小分子肽8％～12％、青钱柳提取物4％～6％、茶藨子叶状层菌发酵菌丝体2％～3％、玉米须提取物5％～7.5％、桑叶提取物6％～9％、苦荞提取物4％～6％、卵磷脂7％～10.5％、茯苓提取物3％～4.5％、显齿蛇葡萄叶粉2％～3％、β-羟基-β甲基丁酸钙1％～1.5％、左旋肉碱0.1％～0.15％、氧化镁0.12％～0.18％、维生素C 0.12％～0.18％、牛磺酸0.08％～0.12％、葡萄糖酸锌0.015％～0.0225％、烟酸0.012％～0.018％、维生素E 0.012％～0.018％以及添加剂0.11541～0.173115。
作为优选，按固体饮料重量百分比计，添加剂由以下成分构成：泛酸0.004％～0.006％、维生素B10.0006％～0.0009％、维生素B20.0006％～0.0009％、维生素B60.0006％～0.0009％、维生素B120.000002％～0.000003％、维生素A 0.00024％～0.00036％、叶酸0.00006％～0.00009％、维生素D30.0000015％～0.00000225％、异麦芽糖醇11.5348965％～17.30234476％。
作为优选，按重量百分比计，包含有：发芽糙米粉29.25％～35.75％、小分子肽9％～11％、青钱柳提取物4.5％～5.5％、茶藨子叶状层菌发酵菌丝体2.25％～2.75％、玉米须提取物5.625％～6.875％、桑叶提取物6.75％～8.25％、苦荞提取物4.5％～5.5％、卵磷脂7.875％～9.625％、茯苓提取物3.375％～4.125％、显齿蛇葡萄叶粉2.25％～2.75％、β-羟基-β甲基丁酸钙1.125％～1.375％、左旋肉碱0.1125％～0.1375％、氧化镁0.135％～0.165％、维生素C 0.135％～0.165％、牛磺酸0.09％～0.11％、葡萄糖酸锌0.016875％～0.020625％、烟酸0.0135％～0.0165％、维生素E 0.0135％～0.0165％。
作为优选，按固体饮料重量百分比计，添加剂由以下成分构成：泛酸0.0045％～0.0055％、维生素B10.000675％～0.000825％、维生素B20.000675％～0.000825％、维生素B6
0.000675％～0.000825％、维生素B120.00000225％～0.00000275％、维生素A0.00027％～0.00033％、叶酸0.0000675％～0.0000825％、维生素D30.0000016875％～0.0000020625％、异麦芽糖醇12.97675857％～15.86048269％。
作为优选，按重量百分比计，包含有：发芽糙米粉32.5％、小分子肽10％、青钱柳提取物5％、茶藨子叶状层菌发酵菌丝体2.5％、玉米须提取物6.25％、桑叶提取物7.5、苦荞提取物5％、卵磷脂8.75％、茯苓提取物3.75％、显齿蛇葡萄叶粉2.5％、β-羟基-β甲基丁酸钙1.25％、左旋肉碱0.125％、氧化镁0.15％、维生素C 0.15％、牛磺酸0.1％、葡萄糖酸锌0.01875％、烟酸0.015％、维生素E 0.015％、泛酸0.005％、维生素B10.00075％、维生素B20.00075％、维生素B60.00075％、维生素B120.0000025％、维生素A 0.0003％、叶酸0.000075％、维生素D30.000001875％、异麦芽糖醇14.41862063％。
一种治疗糖尿病的固体饮料的制备方法，其特征在于：包括如下步骤
(1)按配方称取发芽糙米粉、小分子肽、青钱柳提取物、茶藨子叶状层菌发酵菌丝体、玉米须提取物、桑叶提取物、苦荞提取物、卵磷脂、茯苓提取物、显齿蛇葡萄叶粉、β-羟基-β甲基丁酸钙、左旋肉碱、氧化镁、维生素C、牛磺酸、葡萄糖酸锌、烟酸、维生素E，
(2)将称量好的物料放入总混机中，进行总混操作，总混时间20—30分钟。
(3)对混合后的物料进行分装。
作为优选，分装的含量为35g/袋。
作为优选，配方还含有：泛酸、维生素B1、维生素B2、维生素B6、维生素B12、维生素A、叶酸、维生素D3、异麦芽糖醇。
青钱柳提取物的功效如下：
(1)青钱柳提取物的黄酮：能有效清除体内的氧自由基，改善血液循环，降低胆固醇，扩张冠状血管、预防心脑血管疾病。
(2)青钱柳提取物苷：这是一种天然甜味剂，并且是非热值皂苷类，能够满足高血糖患者对甜味的需求，而不加重病情，同时在降糖、降脂、降压方面具有很好的作用。
(3)青钱柳提取物的多糖：具有良好的降血糖作用，能够有效提高高血糖患者糖耐受量。杯或玻璃杯中，85度左右开水冲泡，以500毫升水为宜，加盖闷泡5分钟。一日3泡，上、下午及晚上个一泡。具有平衡稳定人体糖代谢的贡献，常饮此茶还可降脂降压，凝神健脑，滋补体质，延年益寿，是中老人及长期工作劳累者的最佳健康助手。
发芽糙米粉的功效：
(1)糙米中含有丰富的抗活性氧植酸、阿魏酸等，可以抑制黑色素的产生，使皮肤保持白净，并能促进新陈代谢，预防动脉硬化、内脏功能障碍和癌症等。大量的氨基酸GABA存在于脑和脊髓中，有改善血液循环、增加氧气供应量、抑制神经失调和老年性痴呆症等功效。
(2)此外，发芽糙米粉还保留着更多的镁、钾、钙、锌和铁等人体所必需的微量元素。现代营养学研究发现，糙米中的米糠和胚芽部分含有丰富的维生素B族和维生素E，能提高人体免疫功能，促进血液循环，还能帮助人们消除沮丧烦躁的情绪，使人充满活力。且对肥胖和胃肠障碍有很好的疗效还能有效的调节体内新陈代谢，内分泌异常等。
玉米须提取物的功效：
(1)利尿作用：玉米须提取物对人或家兔均有利尿作用，可增加氯化物排出量，利尿作用主要是肾外性的，对肾脏的作用很弱；
(2)对循环系统的作用
(3)降低血糖作用
(4)利胆、止血作用：玉米须提取物制剂能促进胆汁排泄，降低其粘度，减少其胆色素含量，因而可作为利胆药用于无并发症的慢性胆囊炎、胆汁排出障碍的胆管炎患者。它还能加速血液凝固过程，增加血中凝血酶元含量，提高血小板数，故可作为止血药兼利尿药应用于膀胱及尿路结石。
茶藨子叶状层菌发酵菌丝体的主要功效：
藨子叶状层菌[Phylloporia ribis(Schumach.:Fr.)Ryvarden]是一种常见真菌,民间广泛用于抗炎、抗病毒、清热解毒、消肿利咽、治疗肿瘤和糖尿病等药理学作用。茶藨子叶状层菌具有目前国内外已经对该菌进行了初步的药理学研究,从中发现了白桦脂酸、麦角甾醇、β-D-葡聚糖、Hispidin及其衍生物和叶绿酸-C等生理活性物质。
桑叶提取物的主要功效：
(1)调节血糖、疏散风热、清肺润燥，清肝明目。用于风热感冒、肺热咳嗽、头痛头晕、目赤晕花等。
(2)桑叶提取物的降血糖作用是通过两个途径实现的：一是通过生物碱DNJ(1-脱氧野尻霉素)对二糖类分解酶活性产生抑制作用，从而抑制小肠对双糖的吸收，降低食后血糖的高峰值(Kimura，1995)；二是通过桑叶提取物生物碱fagomine及桑叶提取物多糖促进β细胞分必胰岛素，而胰岛素可以促进细胞对糖的利用、肝糖原合成以及改善糖代谢，最终达到降血糖的效果。
苦荞提取物的成份与功效：
(1)苦荞的生物类黄酮：主要成份是芦丁，又名维生素P。其主要功效是：软化血管，改善微循环，清热解毒、活血化瘀、拔毒生肌、有降血糖、尿糖、血脂、益气提神、加强胰岛素外周作用。而芦丁在其它谷物中几乎没有！
(2)苦荞的微量元素和矿物质：苦荞麦含有多种有益人体健康的无机元素钙、磷、铁、铜、锌和微量元素硒等，镁的含量是小麦面粉的11倍以上，铁元素是其它主粮的2—5倍，锌为1.5倍以上，锰为1.4陪以上，钾为小麦的2倍，大米的2.3倍，黄玉米面的1.5倍。镁、钾的高含量大大增强了苦荞粉的营养保健功能。
苦荞的淀粉：苦荞麦淀粉为支链淀粉，含大量凝胶黏液，加热后呈弱碱性，对胃酸过多有抑制作用。对病灶可起到缓解和屏障保护作用。
(3)苦荞的维生素：苦荞中含有丰富的维生素。维生素B2的含量是玉米粉和大米的2—10倍。维生素PP有降低人体血脂和胆固醇的作用，是治疗高血压、心血管病的重要辅助药物；尤其是对老年患者具有特别疗效，能降低微血管脆性和渗透性，恢复其弹性。对防止脑溢血、维持眼循环，保护和增进视力有效。维生素E中r生育酚含量较高，对防止氧化和治疗不育症有效，并有促进细胞再生、防止衰老作用。
(4)苦荞的纤维素：也称膳食纤维。含量达到1.6％，是普通米面的八倍之多，具有整肠通便，清除体内毒素的良好功效，是人体消化系统的清道夫。
(5)苦荞的脂肪：苦荞麦中油酸和亚油酸含量极高，而亚油酸是人体最重要的脂肪酸，体内不能合成！对幼儿有促进生长发育作用。对成年人可防止冠心病。同时因含有抑制皮肤生成黑色素的物质(2，4二羟基顺式肉桂酸)，有预防雀斑及老年斑的作用，是美容护肤的佳品。世居高山的彝族女子唇红齿白，皮肤细嫩。
(6)苦荞的蛋白质：含有19种天然氨基酸，总含量高达11.82％。特别含有一般植物如小麦、稻米所缺少的赖氨酸，富含精氨酸和组氨酸。并且苦荞蛋白有近三分之一为清理蛋白，可清理体内毒素和异物,而且，苦荞蛋白由于富含精氨酸，可以防止体脂增加。
另外，苦荞还含有其它粮食作物不具备的叶绿素。
本发明与现有技术相比，具有以下优点和效果：本发明具有能够抑制血糖上升的效果，并且可以让糖尿病患者摆脱注射胰岛素的困扰,可逐渐代替胰岛素，让患者摆脱对胰岛素及西药的依赖，从而避免胰岛素的副作用。
具体实施方式
下面通过实施例对本发明作进一步的详细说明，以下实施例是对本发明的解释而本发明并不局限于以下实施例。
按照以下方式制备治疗糖尿病的固体饮料，包括如下步骤
(1)称取发芽糙米粉325000g、小分子肽100000g、青钱柳提取物50000g、茶藨子叶状层菌发酵菌丝体25000g、玉米须提取物62500g、桑叶提取物75000g、苦荞提取物50000g、卵磷脂87500g、茯苓提取物37500g、显齿蛇葡萄叶粉25000g、β-羟基-β甲基丁酸钙12500g、左旋肉碱1250g、氧化镁1500g、维生素C 1500g、牛磺酸1000g、葡萄糖酸锌187.5g、烟酸150g、维生素E 150g、泛酸50g、维生素B17.5g、维生素B27.5g、维生素B67.5g、维生素B120.025g、维生素A 3g、叶酸0.75g、维生素D30.01875g、异麦芽糖醇145286.2g，
(2)将称量好的物料放入总混机中，进行总混，总混时间20—30分钟。
(3)对混合后的物料进行分装操作，随时检查装量、气密性、包装袋平整无皱纹。分装的含量为35g/袋。
将上述固体饮料经过糖尿病患者服用，获得如下数据：
服用对象一：男，55周岁，糖尿病患病史3年，血糖居高不下，服用2个月，服用前每天注射胰岛素26个单位，现今餐后血糖值6.5mmol/L，已摆脱注射胰岛素，每日2次，每次35g/袋。
服用对象二：男，58周岁，糖尿病患病史6年，血糖居高不下，服用2个月，服用前每天注射胰岛素34个单位，现今空腹血糖值为6mmol/L以下，已摆脱注射胰岛素，每日2次，每次35g/袋。
服用对象三：男，52周岁，糖尿病患病史4年，血糖居高不下，服用2个月，服用前每天注射胰岛素28个单位，现今空腹血糖值为7mmol/L左右，每天注射胰岛素8个单位，每日2次，每次35g/袋。
服用对象四：女，67周岁，糖尿病患病史2年，血糖居高不下，服用2个月，服用前每天注射胰岛素32个单位，现今空腹血糖值为10mmol/L左右，每天注射胰岛素12个单位，每日2次，每次35g/袋。
通过实验对比，证实了本发明具有能够抑制血糖上升的效果，并且可以让糖尿病患者摆脱注射胰岛素的困扰。
本说明书中所描述的以上内容仅仅是对本发明所作的举例说明。本发明所属技术领域的技术人员可以对所描述的具体实施例做各种各样的修改或补充或采用类似的方式替代，只要不偏离本发明说明书的内容或者超越本权利要求书所定义的范围，均应属于本发明的保护范围。
Claims (8)
1.一种治疗糖尿病的固体饮料，其特征在于：按重量百分比计，由以下成分构成，发芽糙米粉26％～39％、小分子肽8％～12％、青钱柳提取物4％～6％、茶藨子叶状层菌发酵菌丝体2％～3％、玉米须提取物5％～7.5％、桑叶提取物6％～9％、苦荞提取物4％～6％、卵磷脂7％～10.5％、茯苓提取物3％～4.5％、显齿蛇葡萄叶粉2％～3％、β-羟基-β甲基丁酸钙1％～1.5％、左旋肉碱0.1％～0.15％、氧化镁0.12％～0.18％、维生素C 0.12％～0.18％、牛磺酸0.08％～0.12％、葡萄糖酸锌0.015％～0.0225％、烟酸0.012％～0.018％、维生素E 0.012％～0.018％以及添加剂0.11541～0.173115。
2.根据权利要求1所述的治疗糖尿病的固体饮料，其特征在于：按固体饮料重量百分比计，添加剂由以下成分构成：泛酸0.004％～0.006％、维生素B1 0.0006％～0.0009％、维生素B2 0.0006％～0.0009％、维生素B6 0.0006％～0.0009％、维生素B12 0.000002％～0.000003％、维生素A 0.00024％～0.00036％、叶酸0.00006％～0.00009％、维生素D30.0000015％～0.00000225％、异麦芽糖醇11.5348965％～17.30234476％。
3.根据权利要求1所述的治疗糖尿病的固体饮料，其特征在于：按重量百分比计，包含有：发芽糙米粉29.25％～35.75％、小分子肽9％～11％、青钱柳提取物4.5％～5.5％、茶藨子叶状层菌发酵菌丝体2.25％～2.75％、玉米须提取物5.625％～6.875％、桑叶提取物6.75％～8.25％、苦荞提取物4.5％～5.5％、卵磷脂7.875％～9.625％、茯苓提取物3.375％～4.125％、显齿蛇葡萄叶粉2.25％～2.75％、β-羟基-β甲基丁酸钙1.125％～1.375％、左旋肉碱0.1125％～0.1375％、氧化镁0.135％～0.165％、维生素C 0.135％～0.165％、牛磺酸0.09％～0.11％、葡萄糖酸锌0.016875％～0.020625％、烟酸0.0135％～0.0165％、维生素E 0.0135％～0.0165％。
4.根据权利要求2所述的治疗糖尿病的固体饮料，其特征在于：按固体饮料重量百分比计，添加剂由以下成分构成：泛酸0.0045％～0.0055％、维生素B1 0.000675％～0.000825％、维生素B2 0.000675％～0.000825％、维生素B6 0.000675％～0.000825％、维生素B12 0.00000225％～0.00000275％、维生素A 0.00027％～0.00033％、叶酸0.0000675％～0.0000825％、维生素D3 0.0000016875％～0.0000020625％、异麦芽糖醇12.97675857％～15.86048269％。
5.根据权利要求1所述的治疗糖尿病的固体饮料，其特征在于：按重量百分比计，包含有：发芽糙米粉32.5％、小分子肽10％、青钱柳提取物5％、茶藨子叶状层菌发酵菌丝体2.5％、玉米须提取物6.25％、桑叶提取物7.5、苦荞提取物5％、卵磷脂8.75％、茯苓提取物3.75％、显齿蛇葡萄叶粉2.5％、β-羟基-β甲基丁酸钙1.25％、左旋肉碱0.125％、氧化镁0.15％、维生素C 0.15％、牛磺酸0.1％、葡萄糖酸锌0.01875％、烟酸0.015％、维生素E0.015％、泛酸0.005％、维生素B1 0.00075％、维生素B2 0.00075％、维生素B6 0.00075％、维生素B12 0.0000025％、维生素A 0.0003％、叶酸0.000075％、维生素D3 0.000001875％、异麦芽糖醇14.41862063％。
6.一种根据权利要求1-5中任一所述所述的治疗糖尿病的固体饮料的制备方法，其特征在于：包括如下步骤
(1)按配方称取发芽糙米粉、小分子肽、青钱柳提取物、茶藨子叶状层菌发酵菌丝体、玉米须提取物、桑叶提取物、苦荞提取物、卵磷脂、茯苓提取物、显齿蛇葡萄叶粉、β-羟基-β甲基丁酸钙、左旋肉碱、氧化镁、维生素C、牛磺酸、葡萄糖酸锌、烟酸、维生素E，
(2)将称量好的物料放入总混机中，进行总混操作，总混时间20—30分钟。
(3)对混合后的物料进行分装。
7.根据权利要求6所述的制备方法，其特征在于：分装的含量为35g/袋。
8.根据权利要求6所述的制备方法，其特征在于：配方还含有：泛酸、维生素B1、维生素B2、维生素B6、维生素B12、维生素A、叶酸、维生素D3、异麦芽糖醇。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811179109.0A CN109170470A (zh) | 2018-10-10 | 2018-10-10 | 一种治疗糖尿病的固体饮料及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811179109.0A CN109170470A (zh) | 2018-10-10 | 2018-10-10 | 一种治疗糖尿病的固体饮料及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109170470A true CN109170470A (zh) | 2019-01-11 |
Family
ID=64947824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811179109.0A Pending CN109170470A (zh) | 2018-10-10 | 2018-10-10 | 一种治疗糖尿病的固体饮料及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109170470A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111406866A (zh) * | 2020-04-15 | 2020-07-14 | 杭州娃哈哈科技有限公司 | 一种降血糖固体饮料及其制备方法 |
| CN112205617A (zh) * | 2019-07-11 | 2021-01-12 | 天赋能健康产业集团股份有限公司 | 一种适宜糖尿病及需要控制血糖人群食用的膳食 |
| CN115677869A (zh) * | 2022-09-14 | 2023-02-03 | 临沂大学 | 一种金芝多糖的制备方法及其用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101496580A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种供糖尿病患者食用含短肽的特殊膳食用食品配方 |
| CN103829164A (zh) * | 2014-03-26 | 2014-06-04 | 安徽燕之坊食品有限公司 | 一种发芽糙米保健食品及其制备方法 |
| CN104856003A (zh) * | 2015-04-23 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 糖尿病非全营养配方食品 |
| CN105249176A (zh) * | 2014-12-09 | 2016-01-20 | 南京农业大学 | 一种适合糖尿病人食用的发芽糙米膨化食品及其生产方法 |
| CN108523138A (zh) * | 2017-03-02 | 2018-09-14 | 劲膳美食品股份有限公司 | 一种降血糖代餐粉 |
| CN108546305A (zh) * | 2018-04-23 | 2018-09-18 | 哈尔滨商业大学 | 一种发芽糙米多糖组合物及其制备方法和应用 |
-
2018
- 2018-10-10 CN CN201811179109.0A patent/CN109170470A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101496580A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种供糖尿病患者食用含短肽的特殊膳食用食品配方 |
| CN103829164A (zh) * | 2014-03-26 | 2014-06-04 | 安徽燕之坊食品有限公司 | 一种发芽糙米保健食品及其制备方法 |
| CN105249176A (zh) * | 2014-12-09 | 2016-01-20 | 南京农业大学 | 一种适合糖尿病人食用的发芽糙米膨化食品及其生产方法 |
| CN104856003A (zh) * | 2015-04-23 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 糖尿病非全营养配方食品 |
| CN108523138A (zh) * | 2017-03-02 | 2018-09-14 | 劲膳美食品股份有限公司 | 一种降血糖代餐粉 |
| CN108546305A (zh) * | 2018-04-23 | 2018-09-18 | 哈尔滨商业大学 | 一种发芽糙米多糖组合物及其制备方法和应用 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112205617A (zh) * | 2019-07-11 | 2021-01-12 | 天赋能健康产业集团股份有限公司 | 一种适宜糖尿病及需要控制血糖人群食用的膳食 |
| CN111406866A (zh) * | 2020-04-15 | 2020-07-14 | 杭州娃哈哈科技有限公司 | 一种降血糖固体饮料及其制备方法 |
| CN115677869A (zh) * | 2022-09-14 | 2023-02-03 | 临沂大学 | 一种金芝多糖的制备方法及其用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103263608B (zh) | 一种排毒养颜的中药原粉 | |
| CN102224891B (zh) | 一种糖醇蜂蜜苹果酱及其制备方法 | |
| CN105942498A (zh) | 具有治疗糖尿病作用的功能性营养食品组合及其制备方法 | |
| CN101317615A (zh) | 一种银棘茶饮料及其制备方法 | |
| CN106214989A (zh) | 一种抗衰老、改善记忆力的鹿血保健药酒及其制备方法 | |
| CN109170470A (zh) | 一种治疗糖尿病的固体饮料及其制备方法 | |
| CN107455625A (zh) | 一种具有抗疲劳减肥功能的植物营养素饮料及其制备工艺 | |
| CN102048224A (zh) | 一种祛黄褐斑美容养颜红枣保健饮料及其生产工艺 | |
| CN105232907A (zh) | 一种补肾壮阳饮料及其制备方法 | |
| CN101773595A (zh) | 清肝明目中药茶 | |
| CN103952278A (zh) | 玛咖矿泉酒及其制作方法 | |
| CN108524673A (zh) | 一种中药组合物及其应用 | |
| CN102920806B (zh) | 安神降压中药茶 | |
| CN101669624B (zh) | 一种具有改善妇女贫血功能的中药八宝茶及其制备方法 | |
| CN102961525A (zh) | 一种用于减肥、辅助降血脂的药物组合物及其口服液制备方法 | |
| CN102008099B (zh) | 红枣养颜饮料 | |
| CN103461585B (zh) | 补气养生中药茶 | |
| CN101543295A (zh) | 一种降压降脂保健茶 | |
| CN101455359A (zh) | 一种活血降脂益寿的口服制剂及制备方法 | |
| CN105249440A (zh) | 一种阿胶糕 | |
| CN110559389A (zh) | 一种用于高尿酸、痛风和风湿病的中药酒及制备方法 | |
| CN109452417A (zh) | 一种纯天然清脂减肥茶饮料及其制备方法 | |
| CN113749152A (zh) | 一种健康养生强身饮品及其制备方法 | |
| CN1528182A (zh) | 一种保健食品及其制备方法 | |
| CN102579688B (zh) | 菊麻降压中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190111 |